Editas Medicine Sets Pricing for Common Stock Offering, Expects to Raise $125 Million
Cambridge-based clinical-stage genome editing company, Editas Medicine, Inc. (Nasdaq: EDIT), has announced the pricing of an underwritten offering of 12,500,000 shares of its.